Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > New Press Release - Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform

<< Previous

Bullboard Posts

Next >>

Comment by Qwerty54321on Mar 28, 2024 5:24pm

51 Views

Post# 35959168

RE:RE:RE:RE:RE:New Press Release - Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology(TM) Platform

How many green days in a row is that? Am I jinxing tomorrow?

Qwerty54321 wrote:
palinc2000 wrote: Qwerty
Is this back to the drawing board?
Can you educate us ?

More of the same rather than back to the drawing board!

It's more great preclinical. Like Wino it's ticking boxes for me but we are really still just waiting for clinical confirmation.